Christopher is based in London and Dublin and is an IP litigation specialist. He graduated in Chemistry and spent time as a research chemist. His principal area of expertise is pharmaceutical patent litigation for both innovator and generic/biosimilar clients. Christopher has significant experience of leading multi-jurisdictional teams and managing and coordinating patent litigation.

Christopher's experience

  • Advised Teva Pharmaceutical Ltd in their patent litigation against BioMarin in respect of the product sapropterin, a life-changing drug for PKU sufferers. A campaign by a cross party group of MPs and the Daily Express to make this drug available shone a light on its importance for patients.

  • Advised Teva Pharmaceutical Industries Ltd in their successful 2022 trial against Novartis in respect of their deferasirox product. The case considered important legal question about numerical limits in respect of the Doctrine of Equivalents and the role of the Skilled Team.

  • Acted for Teva Pharmaceutical Industries Ltd in respect of their mirabegron product, co-counselling alongside Sandoz, in a case that considered key issues of plausibility at the UK trial.

  • Advised the UK government on its agreement with Pfizer and BioNTech for the supply of a vaccine against COVID-19. The Pfizer BioNTech vaccine was the first approved for use in the world and is seen as a key weapon in the fight against Covid

  • Acting for Juul Labs Inc., a major supplier of e-cigarettes, in proceedings against QuickJuul Limited to prevent the sale of counterfeit goods as well as in obtaining innovative injunctive relief to attempt to effectively shutdown the cross border supply of the counterfeit goods. The relief involves obtaining multiple orders including search orders, worldwide freezing orders, trade mark infringement proceedings, third party disclosure orders, as well as applications for committal proceedings.

  • Acted in patent proceedings for Teva Industries Ltd against Chiesi in respect of a combination of beclomethasone dipropionate and formoterol fumarate to treat asthma and COPD. This led to a precedent setting UK ruling on the threshold for a threat of patent infringement.

  • Acted for JUUL Labs, Inc. in patent infringement proceedings in the UK against J Well SA in relation to electronic cigarettes.

  • Acted for Accord Healthcare in the High Court and Court of Appeal on the revocation of the formulation patent relating to Allergan's ophthalmic medicine Lumigan 0.01%.

  • Acted for the British Generic Manufacturers Association as intervenor in the Supreme Court appeals relating to Lyrica (second medical use) and Cialis (obviousness).

  • Acted for Accord Healthcare in the High Court on the revocation of three patents relating to Celgene's blockbuster multiple myeloma product Revlimid.

Credentials

  • 2017
    Qualified Ireland
  • 2016
    Joined Pinsent Masons
  • 2008
    University of Bristol - Postgraduate Diploma in Intellectual Property Law & Practice
  • 2007
    Qualified - England and Wales
  • 2005
    BPP Law School - Legal Practice Course, Distinction
  • 2005
    Herbert Smith Freehills LLP - Senior Associate
  • 2004
    BPP Law School - Postgraduate Diploma in Law, Commendation
  • 2003
    University of Bristol - BSc (Hons) First Class, Chemistry
Load More

Out-Law / Insight by Christopher Sharp

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.